Table 2. Percentage of patients receiving guideline-based care and mean number of fractions delivered.

Cancer Type	Measure	2011 Fee-For-Service	2013 Case Rate	RR	95% CI	P-Value of Change in Mean
Bone mets.				2.0†	(1.21–3.24)
	%	30.2%	60.0%
	n	43	75
	Mean	13.7	11.4			0.03†
	±SD	5.5	5.6
Breast				1.0	(0.94–1.04)
	%	95.9%‡	95.1%§
	n	123	143
	Mean	29.7	30.4			0.31
	±SD	5.1	6.0
Lung				1.0	(0.89–1.09)
	%	91.5%	91.5%
	n	59	71
	Mean	27.4	27.1			0.84
	±SD	9.3	9.2
Prostate				1.1†	(1.01–1.15)
	%	88.5%	95.2%
	N	157	189
	2D3D mean	n/a	n/a			n/a
	2D3D ±SD	n/a	n/a
	2D3D n	0	0
	IMRT mean	37.4	41.1			0.00†
	IMRT ±SD	8.7	6.1
	IMRT n	157	189
Skin
	%	100.0%	91.9%	0.9	(0.84–1.01)
	n	51	37
	2D3D mean	22.6	24.2			0.20
	2D3D ±SD	4.0	6.5
	2D3D n	50	34
	IMRT mean	Redacted	Redacted			Redacted
	IMRT ±SD	Redacted	Redacted
	IMRT n	1	3
Overall				1.0	(0.98–1.08)
	%	86.6	89.3
	n	433	515*

Results redacted for groups with n<10.

CI = confidence interval, mets. = metastases, RR = relative risk, SD = standard deviation.

*An intent-to-treat approach was used for this population where case rates were introduced, yet not all patients were covered under the case rate arrangement. Results for 2D3D and IMRT fractionation are displayed separately for prostate and skin cancer due to the differences in the guidelines.

^†P < .05.

^‡16–21 fractions were delivered to 8% of those who received guideline-based care (9/118).

^§16–21 fractions were delivered to 10% of those who received guideline-based care (13/136).